Treatment response to bortezomib in multiple myeloma correlates
with plasma hepatocyte growth factor concentration and bone
marrow thrombospondin concentration

J 2010

Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration

POUR, Luděk; Hana ŠVÁCHOVÁ; Zdeněk ADAM; Martina ALMASI; Dana KRÁLOVÁ et al.

Základní údaje

Originální název

Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration

Autoři

POUR, Luděk; Hana ŠVÁCHOVÁ; Zdeněk ADAM; Martina ALMASI; Dana KRÁLOVÁ; Tomáš BÜCHLER; Lucie KOVÁŘOVÁ; Marta KREJČÍ; Jaroslav MICHÁLEK; Miroslav PENKA; Jiří VORLÍČEK a Roman HÁJEK

Vydání

European Journal of Haematology, 2010, 0902-4441

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.785

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/10:00052598

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1111/j.1600-0609.2009.01396.x

UT WoS

000275768900008

Klíčová slova anglicky

angiogenesis; chemokines; bortezomib; multiple myeloma; therapeutic response

Příznaky

Mezinárodní význam

Změněno: 20. 4. 2012 12:03, Mgr. Michal Petr

Anotace

V originále

Multiple myeloma (MM) is associated with increased rate of bone marrow angiogenesis. Increased concentration of hepatocyte growth factor (HGF) is associated with poor prognosis in patients treated with conventional chemotherapy or thalidomide. We have shown previously that decreased level of thrombospondin, an angiogenesis inhibitor, correlates with poor response to high-dose chemotherapy. The aim of our current study was to evaluate association between therapeutic response to bortezomib and thrombospondin and HGF levels. Peripheral blood plasma concentration of HGF and bone marrow plasma concentration of thrombospondin were measured in patients with MM prior to the initiation of bortezomib therapy. Overall, 58 patients were enrolled, 44/58 (76%) of them with relapsed disease. Treatment outcomes were analyzed for possible associations with pretreatment HGF and thrombospondin levels. Patients who achieved complete response had significantly higher pretreatment HGF levels and lower pretreatment thrombospondin levels than others. More than 70% of patients with low pretreatment HGF and high pretreatment thrombospondin concentrations achieved very good partial response or complete response, in contrast to only 20% of patients with high HGF and low thrombospondin levels. High pretreatment thrombospondin and low pretreatment HGF concentrations are associated with therapeutic response to bortezomib in patients with MM.

Návaznosti

LC06027, projekt VaV

Název: Univerzitní výzkumné centrum - Česká myelomová skupina (Akronym: LC MGUS)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Univerzitní výzkumné centrum - Česká myelomová skupina (URC - CMG)

MSM0021622434, záměr

Název: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

Citovat

POUR, Luděk; Hana ŠVÁCHOVÁ; Zdeněk ADAM; Martina ALMASI; Dana KRÁLOVÁ; Tomáš BÜCHLER; Lucie KOVÁŘOVÁ; Marta KREJČÍ; Jaroslav MICHÁLEK; Miroslav PENKA; Jiří VORLÍČEK a Roman HÁJEK. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. European Journal of Haematology. 2010, roč. 84, č. 4, s. 332-336. ISSN 0902-4441. Dostupné z: https://doi.org/10.1111/j.1600-0609.2009.01396.x.

@article{944233,
   author = {Pour, Luděk and Šváchová, Hana and Adam, Zdeněk and Almasi, Martina and Králová, Dana and Büchler, Tomáš and Kovářová, Lucie and Krejčí, Marta and Michálek, Jaroslav and Penka, Miroslav and Vorlíček, Jiří and Hájek, Roman},
   article_number = {4},
   doi = {https://doi.org/10.1111/j.1600-0609.2009.01396.x},
   keywords = {angiogenesis; chemokines; bortezomib; multiple myeloma; therapeutic response},
   language = {eng},
   issn = {0902-4441},
   journal = {European Journal of Haematology},
   title = {Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration},
   url = {http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2009.01396.x/pdf},
   volume = {84},
   year = {2010}
}

TY  - JOUR
ID  - 944233
AU  - Pour, Luděk - Šváchová, Hana - Adam, Zdeněk - Almasi, Martina - Králová, Dana - Büchler, Tomáš - Kovářová, Lucie - Krejčí, Marta - Michálek, Jaroslav - Penka, Miroslav - Vorlíček, Jiří - Hájek, Roman
PY  - 2010
TI  - Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration
JF  - European Journal of Haematology
VL  - 84
IS  - 4
SP  - 332-336
EP  - 332-336
SN  - 09024441
KW  - angiogenesis
KW  - chemokines
KW  - bortezomib
KW  - multiple myeloma
KW  - therapeutic response
UR  - http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2009.01396.x/pdf
N2  - Multiple myeloma (MM) is associated with increased rate of bone marrow angiogenesis. Increased concentration of hepatocyte growth factor (HGF) is associated with poor prognosis in patients treated with conventional chemotherapy or thalidomide. We have shown previously that decreased level of thrombospondin, an angiogenesis inhibitor, correlates with poor response to high-dose chemotherapy. The aim of our current study was to evaluate association between therapeutic response to bortezomib and thrombospondin and HGF levels. Peripheral blood plasma concentration of HGF and bone marrow plasma concentration of thrombospondin were measured in patients with MM prior to the initiation of bortezomib therapy. Overall, 58 patients were enrolled, 44/58 (76%) of them with relapsed disease. Treatment outcomes were analyzed for possible associations with pretreatment HGF and thrombospondin levels. Patients who achieved complete response had significantly higher pretreatment HGF levels and lower pretreatment thrombospondin levels than others. More than 70% of patients with low pretreatment HGF and high pretreatment thrombospondin concentrations achieved very good partial response or complete response, in contrast to only 20% of patients with high HGF and low thrombospondin levels. High pretreatment thrombospondin and low pretreatment HGF concentrations are associated with therapeutic response to bortezomib in patients with MM.
ER  -

POUR, Luděk; Hana ŠVÁCHOVÁ; Zdeněk ADAM; Martina ALMASI; Dana KRÁLOVÁ; Tomáš BÜCHLER; Lucie KOVÁŘOVÁ; Marta KREJČÍ; Jaroslav MICHÁLEK; Miroslav PENKA; Jiří VORLÍČEK a Roman HÁJEK. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. \textit{European Journal of Haematology}. 2010, roč.~84, č.~4, s.~332-336. ISSN~0902-4441. Dostupné z: https://doi.org/10.1111/j.1600-0609.2009.01396.x.

Přehled o publikaci